Acutus Medical, INC

Acutus Medical, Inc. (OTC: AFIB) announced a significant increase in revenue from continuing operations for the full year 2024, alongside improvements in operating loss and gross margin.

Acutus Medical terminates its registration rights agreement with Deerfield Funds as part of its plan to deregister its common stock and cease periodic reporting obligations.

Acutus Medical is significantly downsizing its operations and transitioning its CEO and CFO to consulting roles as it focuses on fulfilling its obligations to Medtronic for left-heart access product manufacturing.

Acutus Medical has amended its credit agreement with Deerfield Partners, adjusting the loan amortization schedule and increasing the exit fee.

Acutus Medical reports a 156% year-over-year increase in third-quarter revenue from continuing operations, alongside a strategic realignment towards left-heart access products.

Acutus Medical has reached a settlement with Biotronik, resolving a dispute over multiple agreements and terminating those agreements, while also agreeing to potential future payments based on certain events.

Acutus Medical's Q3 2024 results show a significant increase in revenue driven by its manufacturing agreement with Medtronic, despite continued losses from discontinued operations.

Acutus Medical's Q2 2024 results show a significant increase in revenue due to its strategic shift to manufacturing for Medtronic, despite continued losses.

Acutus Medical's Q1 2024 results reflect a strategic realignment towards manufacturing for Medtronic, alongside a Nasdaq delisting and a shift to OTC trading.

Acutus Medical's 2024 10-K filing reveals a company in transition, marked by strategic restructuring, operational downsizing, and delisting from Nasdaq, as it focuses on its manufacturing partnership with Medtronic.

Acutus Medical is restructuring its business to focus solely on manufacturing left-heart access products for Medtronic, discontinuing its mapping and ablation businesses.

James E. Flynn, a director by deputization, and Deerfield Management Company, L.P. reported changes in their beneficial ownership of Acutus Medical, Inc. securities, including the termination of warrants and conversion of preferred stock.

Takeo Mukai, CFO of Acutus Medical, Inc., reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Acutus Medical will hold its annual stockholders meeting on June 13, 2024, to elect directors and ratify the selection of KPMG LLP as its independent auditor.

Acutus Medical will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the selection of KPMG LLP as its independent accounting firm.

Deerfield Management has updated its Schedule 13D filing for Acutus Medical, Inc., reflecting the cancellation of warrants held by its funds after the company completed its SEC deregistration and paid a termination fee.

Deerfield Funds and Acutus Medical have amended their credit agreement to facilitate restructuring, including the termination of warrants and registration rights, and the issuance of contingent value rights.